Lanreotide
SOMATULINE
What it isLong-acting somatostatin-receptor agonist; acromegaly and neuroendocrine tumors.
Why this oneIts deep-subcutaneous prefilled syringe can be administered at home, unlike intramuscular octreotide depot.
What limits itGallstones, glucose dysregulation, and injection-site nodules limit use; it suppresses insulin as well as growth hormone.
FDA-approved for
- acromegaly/NETs (2007)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Acromegaly | Adults | 90 mg SC q4wk ×3 months | Adjust by GH/IGF-1 (60-120 mg q4wk) | 120 mg q4wk |
| GEP-NETs | Adults | 120 mg SC q4wk | 120 mg q4wk | 120 mg q4wk |
| Carcinoid syndrome | Adults | 120 mg SC q4wk | 120 mg q4wk | 120 mg q4wk |
Titration After 3 months, adjust acromegaly dose based on GH and/or IGF-1 levels
Renal Reduce starting dose in moderate/severe renal impairment (acromegaly) — see PI
Hepatic Reduce starting dose in moderate/severe hepatic impairment (acromegaly) — see PI
Do not give an additional carcinoid-syndrome dose if patient is already treated with lanreotide for GEP-NET
Instructions
- Deep subcutaneous injection only, by a healthcare provider, into superior external quadrant of buttock; alternate sides
- Remove from refrigerator 30 min before use; inspect for particulates/discoloration
Cautions
- Cholelithiasis and complications (monitor)
- Hyperglycemia and hypoglycemia (monitor glucose)
- Cardiovascular abnormalities (bradycardia)
- Thyroid function decrease
- Steatorrhea and malabsorption of dietary fats
Adverse reactions
- Diarrhea
- Cholelithiasis
- Abdominal pain
- Nausea
- Injection site reactions
Pregnancy Limited data; animal studies show decreased embryo/fetal survival
Lactation Unknown in human milk; advise not to breastfeed during treatment and for 6 months after last dose
NO BOXED WARNINGS
Principal riskGallstones with prolonged use
Cost, est. cash$20–$1,500/month
Generic entryBy 2023
Classes and tags
Clinical profile
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Mechanism of action: Lanreotide ballicule
